Pharmacokinetics of drugs for pediatric pulmonary hypertension

Kouichi Nakau, Masaya Sugimoto, Hideharu Oka, Aya Kajihama, Jun Maeda, Hiroyuki Yamagishi, Naoya Kamiyama, Yoshikazu Tasaki, Hiroki Kajino, Hiroshi Azuma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Over the past few years, several drugs, each with a different mechanism, have been developed for the treatment of pulmonary hypertension (PH) and are now prescribed in the clinical setting. While the optimal doses of these drugs in adults have been determined, the optimal dose in children, however, is unclear. The aim of this study was therefore, to measure blood drug levels and analyze the pharmacokinetics of two such drugs in children. Methods: From April 2010 to May 2015, we prospectively enrolled 23 children with PH for treatment with bosentan and/or tadalafil. Twenty children were treated with bosentan and 19 received tadalafil. Sixteen children were given both drugs. Blood samples were collected after 2 weeks of treatment, and blood drug levels measured using high-performance liquid chromatography. Results: For both drugs, the peak plasma concentration was lower and the half-life was shorter than the known values in adults. The blood trough level of bosentan significantly correlated with its dose, but no such correlation was seen for tadalafil. For both drugs, no correlation was observed between age and blood drug levels. Conclusions: Oral dosing with bosentan and tadalafil in children may not achieve therapeutic blood concentration. Thus, the optimal dosing must be established individually while monitoring blood drug level.

Original languageEnglish
Pages (from-to)1112-1117
Number of pages6
JournalPediatrics International
Volume58
Issue number11
DOIs
Publication statusPublished - 2016 Nov 1

Fingerprint

Pulmonary Hypertension
Pharmacokinetics
Pediatrics
Pharmaceutical Preparations
Drug Monitoring
Therapeutics
Half-Life
High Pressure Liquid Chromatography
Tadalafil
bosentan

Keywords

  • bosentan
  • pharmacokinetics
  • pulmonary hypertension
  • tadalafil

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Nakau, K., Sugimoto, M., Oka, H., Kajihama, A., Maeda, J., Yamagishi, H., ... Azuma, H. (2016). Pharmacokinetics of drugs for pediatric pulmonary hypertension. Pediatrics International, 58(11), 1112-1117. https://doi.org/10.1111/ped.12997

Pharmacokinetics of drugs for pediatric pulmonary hypertension. / Nakau, Kouichi; Sugimoto, Masaya; Oka, Hideharu; Kajihama, Aya; Maeda, Jun; Yamagishi, Hiroyuki; Kamiyama, Naoya; Tasaki, Yoshikazu; Kajino, Hiroki; Azuma, Hiroshi.

In: Pediatrics International, Vol. 58, No. 11, 01.11.2016, p. 1112-1117.

Research output: Contribution to journalArticle

Nakau, K, Sugimoto, M, Oka, H, Kajihama, A, Maeda, J, Yamagishi, H, Kamiyama, N, Tasaki, Y, Kajino, H & Azuma, H 2016, 'Pharmacokinetics of drugs for pediatric pulmonary hypertension', Pediatrics International, vol. 58, no. 11, pp. 1112-1117. https://doi.org/10.1111/ped.12997
Nakau K, Sugimoto M, Oka H, Kajihama A, Maeda J, Yamagishi H et al. Pharmacokinetics of drugs for pediatric pulmonary hypertension. Pediatrics International. 2016 Nov 1;58(11):1112-1117. https://doi.org/10.1111/ped.12997
Nakau, Kouichi ; Sugimoto, Masaya ; Oka, Hideharu ; Kajihama, Aya ; Maeda, Jun ; Yamagishi, Hiroyuki ; Kamiyama, Naoya ; Tasaki, Yoshikazu ; Kajino, Hiroki ; Azuma, Hiroshi. / Pharmacokinetics of drugs for pediatric pulmonary hypertension. In: Pediatrics International. 2016 ; Vol. 58, No. 11. pp. 1112-1117.
@article{0d3ebfa7ab3642e5b85d432f58c51b70,
title = "Pharmacokinetics of drugs for pediatric pulmonary hypertension",
abstract = "Background: Over the past few years, several drugs, each with a different mechanism, have been developed for the treatment of pulmonary hypertension (PH) and are now prescribed in the clinical setting. While the optimal doses of these drugs in adults have been determined, the optimal dose in children, however, is unclear. The aim of this study was therefore, to measure blood drug levels and analyze the pharmacokinetics of two such drugs in children. Methods: From April 2010 to May 2015, we prospectively enrolled 23 children with PH for treatment with bosentan and/or tadalafil. Twenty children were treated with bosentan and 19 received tadalafil. Sixteen children were given both drugs. Blood samples were collected after 2 weeks of treatment, and blood drug levels measured using high-performance liquid chromatography. Results: For both drugs, the peak plasma concentration was lower and the half-life was shorter than the known values in adults. The blood trough level of bosentan significantly correlated with its dose, but no such correlation was seen for tadalafil. For both drugs, no correlation was observed between age and blood drug levels. Conclusions: Oral dosing with bosentan and tadalafil in children may not achieve therapeutic blood concentration. Thus, the optimal dosing must be established individually while monitoring blood drug level.",
keywords = "bosentan, pharmacokinetics, pulmonary hypertension, tadalafil",
author = "Kouichi Nakau and Masaya Sugimoto and Hideharu Oka and Aya Kajihama and Jun Maeda and Hiroyuki Yamagishi and Naoya Kamiyama and Yoshikazu Tasaki and Hiroki Kajino and Hiroshi Azuma",
year = "2016",
month = "11",
day = "1",
doi = "10.1111/ped.12997",
language = "English",
volume = "58",
pages = "1112--1117",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Pharmacokinetics of drugs for pediatric pulmonary hypertension

AU - Nakau, Kouichi

AU - Sugimoto, Masaya

AU - Oka, Hideharu

AU - Kajihama, Aya

AU - Maeda, Jun

AU - Yamagishi, Hiroyuki

AU - Kamiyama, Naoya

AU - Tasaki, Yoshikazu

AU - Kajino, Hiroki

AU - Azuma, Hiroshi

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: Over the past few years, several drugs, each with a different mechanism, have been developed for the treatment of pulmonary hypertension (PH) and are now prescribed in the clinical setting. While the optimal doses of these drugs in adults have been determined, the optimal dose in children, however, is unclear. The aim of this study was therefore, to measure blood drug levels and analyze the pharmacokinetics of two such drugs in children. Methods: From April 2010 to May 2015, we prospectively enrolled 23 children with PH for treatment with bosentan and/or tadalafil. Twenty children were treated with bosentan and 19 received tadalafil. Sixteen children were given both drugs. Blood samples were collected after 2 weeks of treatment, and blood drug levels measured using high-performance liquid chromatography. Results: For both drugs, the peak plasma concentration was lower and the half-life was shorter than the known values in adults. The blood trough level of bosentan significantly correlated with its dose, but no such correlation was seen for tadalafil. For both drugs, no correlation was observed between age and blood drug levels. Conclusions: Oral dosing with bosentan and tadalafil in children may not achieve therapeutic blood concentration. Thus, the optimal dosing must be established individually while monitoring blood drug level.

AB - Background: Over the past few years, several drugs, each with a different mechanism, have been developed for the treatment of pulmonary hypertension (PH) and are now prescribed in the clinical setting. While the optimal doses of these drugs in adults have been determined, the optimal dose in children, however, is unclear. The aim of this study was therefore, to measure blood drug levels and analyze the pharmacokinetics of two such drugs in children. Methods: From April 2010 to May 2015, we prospectively enrolled 23 children with PH for treatment with bosentan and/or tadalafil. Twenty children were treated with bosentan and 19 received tadalafil. Sixteen children were given both drugs. Blood samples were collected after 2 weeks of treatment, and blood drug levels measured using high-performance liquid chromatography. Results: For both drugs, the peak plasma concentration was lower and the half-life was shorter than the known values in adults. The blood trough level of bosentan significantly correlated with its dose, but no such correlation was seen for tadalafil. For both drugs, no correlation was observed between age and blood drug levels. Conclusions: Oral dosing with bosentan and tadalafil in children may not achieve therapeutic blood concentration. Thus, the optimal dosing must be established individually while monitoring blood drug level.

KW - bosentan

KW - pharmacokinetics

KW - pulmonary hypertension

KW - tadalafil

UR - http://www.scopus.com/inward/record.url?scp=84996587478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996587478&partnerID=8YFLogxK

U2 - 10.1111/ped.12997

DO - 10.1111/ped.12997

M3 - Article

VL - 58

SP - 1112

EP - 1117

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 11

ER -